Search Results - "Ohuchi, Mayu"

Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis by Suzuki, Mikiko, Yagishita, Shigehiro, Sugihara, Kiyoshi, Ogitani, Yusuke, Nishikawa, Tadaaki, Ohuchi, Mayu, Teishikata, Takashi, Jikoh, Takahiro, Yatabe, Yasushi, Yonemori, Kan, Tamura, Kenji, Hasegawa, Kosei, Hamada, Akinobu

“…We assessed the intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan, T-DXd (known as DS-8201a), a novel HER2-targeted antibody-drug conjugate, using…”
Get full text

Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging by Tsubata, Yukari, Hayashi, Mitsuhiro, Tanino, Ryosuke, Aikawa, Hiroaki, Ohuchi, Mayu, Tamura, Kenji, Fujiwara, Yasuhiro, Isobe, Takeshi, Hamada, Akinobu

“…Although drug distribution in tumor tissues has a significant impact on efficacy, conventional pharmacokinetic analysis has some limitations with regard to its…”
Get full text

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients by Ohuchi, Mayu, Yagishita, Shigehiro, Jo, Hitomi, Akagi, Kazumasa, Inaba Higashiyama, Ryoko, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Horinouchi, Hidehito, Makino, Yoshinori, Yamamoto, Noboru, Ohe, Yuichiro, Hamada, Akinobu

“…•PPK model of 200 mg Q3W pembrolizumab in Japanese patients with NSCLC is developed.•Early change in CL of pembrolizumab correlated with treatment effect and…”
Get full text

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging by Ryu, Shoraku, Ohuchi, Mayu, Yagishita, Shigehiro, Shimoi, Tatsunori, Yonemori, Kan, Tamura, Kenji, Fujiwara, Yasuhiro, Hamada, Akinobu

“…Penetration of nanoparticles into viable tumor regions is essential for an effective response. Mass spectrometry imaging (MSI) is a novel method for evaluating…”
Get full text

High‐performance liquid chromatography–tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples by Tsuchiya, Kiyoto, Ohuchi, Mayu, Yamane, Naoe, Aikawa, Hiroaki, Gatanaga, Hiroyuki, Oka, Shinichi, Hamada, Akinobu

“…A simple sample treatment procedure and sensitive liquid chromatography–tandem mass spectrometry method were developed for the simultaneous quantification of…”
Get full text

The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy by Shinno, Yuki, Goto, Yasushi, Ohuchi, Mayu, Hamada, Akinobu, Nokihara, Hiroshi, Fujiwara, Yasuhiro, Ohe, Yuichiro

“…EGFR tyrosine kinase inhibitors are one of the key drugs for treatment of NSCLC with mutations. In recent times, immune check-point inhibitors (ICIs) have also…”
Get full text

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL by Yagishita, Shigehiro, Goto, Yasushi, Nishio, Makoto, Akamatsu, Hiroaki, Hayashi, Hidetoshi, Miura, Satoru, Tamada, Koji, Kagamu, Hiroshi, Hamada, Akinobu, Ohuchi, Mayu, Gemma, Akihiko, Yoshino, Ichiro, Misumi, Toshihiro, Hata, Akito, Hara, Satoshi, Kijima, Takashi, Masaki, Fujita, Iwasawa, Shunichiro, Nakagawa, Shintaro, Tatsuno, Masahiro, Mitsudomi, Tetsuya

“…This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC…”
Get full text

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC by Jo, Hitomi, Yoshida, Tatsuya, Yagishita, Shigehiro, Ohuchi, Mayu, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Takahashi, Kazuhisa, Motoi, Noriko, Hamada, Akinobu, Ohe, Yuichiro

“…Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced NSCLC. Nevertheless, these responses are limited to a few…”
Get full text

Development of an analytical method to determine E7130 concentration in mouse plasma by micro-sampling using ultra-performance liquid chromatography–high resolution mass spectrometry by Ryu, Shoraku, Hayashi, Yoshiharu, Yagishita, Shigehiro, Takahashi, Ako, Yokoi, Akira, Ohuchi, Mayu, Hamada, Akinobu

“…•E7130 is a novel microtubule inhibitor and a promising ameliorator of the tumor microenvironment.•An analytical method was developed to quantify E7130 in…”
Get full text

Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats by Taguchi, Kazuaki, Hayashi, Yukitaka, Ohuchi, Mayu, Yamada, Hotaka, Yagishita, Shigehiro, Enoki, Yuki, Matsumoto, Kazuaki, Hamada, Akinobu

Get full text

A procedure for method development and protein binding ratio as the indicator of sensitivity with anticancer agents on MALDI mass spectrometry imaging by Hayashi, Yoshiharu, Ohuchi, Mayu, Ryu, Shoraku, Yagishita, Shigehiro, Hamada, Akinobu

“…The concentration and distribution of a drug and its metabolites in tissues are key factors for elucidating both drug efficacy and toxicity in drug…”
Get full text

Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species by Ohuchi, Mayu, Yagishita, Shigehiro, Taguchi, Kazuaki, Goto, Yasushi, Fukahori, Masaru, Enoki, Yuki, Shimada, Takashi, Yamaguchi, Masakazu, Matsumoto, Kazuaki, Hamada, Akinobu

“…•A method to quantify nivolumab in human plasma using LC-MS/MS was validated.•The method for quantifying nivolumab in mouse plasma is the same as for…”
Get full text

Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer by Watabe, Kazuki, Ohno, Izumi, Sakai, Miho, Takahashi, Tomoya, Yamada, Nana, Tohyama, Shodai, Sekine, Yu, Sugihara, Jihei, Ohuchi, Mayu, Nagashima, Hiroki, Takahashi, Koji, Okitsu, Kohichiro, Kan, Motoyasu, Ohyama, Hiroshi, Ohtsuka, Masayuki, Kato, Naoya

“…678 Background: Japanese Clinical Practice Guidelines for Pancreatic Cancer 2022 recommends gemcitabine (GEM) + nab-paclitaxel (nab-PTX) therapy (GnP regimen)…”
Get full text

Histopathologic and genomic profile characteristics of biliary cancers related to pancreaticobiliary maljunction by Tohyama, Shodai, Ohyama, Hiroshi, Ohno, Izumi, Amemiya, Kenji, Hirotsu, Yosuke, Sakai, Miho, Watabe, Kazuki, Yamada, Nana, Sugihara, Jihei, Ohuchi, Mayu, Kan, Motoyasu, Nagashima, Hiroki, Takahashi, Koji, Okitsu, Kohichiro, Mishima, Takashi, Takayashiki, Tsukasa, Mochizuki, Hitoshi, Ohtsuka, Masayuki, Kato, Naoya, Omata, Masao

“…527 Background: Pancreaticobiliary maljunction (PBM) is a congenital malformation in which the pancreatic duct and bile duct anatomically merge outside the…”
Get full text

MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years by Saeki, Sho, Yamanaka, Yuta, Kurata, Takayasu, Watanabe, Kageaki, Hosomi, Yukio, Horinouchi, Hidehito, Ohe, Yuichiro, Nakahara, Yoshiro, Asao, Tetsuhiko, Tsubata, Yukari, Fujita, Yu, Konishi, Jun Sakakibara, Mizugaki, Hidenori, Ohuchi, Mayu, Yagishita, Shigehiro, Hamada, Akinobu

Get full text

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC by Higashiyama, Ryoko Inaba, Yoshida, Tatsuya, Yagishita, Shigehiro, Ohuchi, Mayu, Sakiyama, Naomi, Torasawa, Masahiro, Shirasawa, Masayuki, Masuda, Ken, Shinno, Yuki, Matsumoto, Yuji, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Hamada, Akinobu, Ohe, Yuichiro

“…Administration of 400 mg pembrolizumab every 6 weeks (400 mg Q6W) has been approved on the basis of the results of simulated pharmacokinetic modeling and…”
Get more information

Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older by Yagishita, Shigehiro, Yamanaka, Yuta, Kurata, Takayasu, Watanabe, Kageaki, Hosomi, Yukio, Horinouchi, Hidehito, Ohe, Yuichiro, Nakahara, Yoshiro, Naoki, Katsuhiko, Asao, Tetsuhiko, Takahashi, Kazuhisa, Saeki, Sho, Sakagami, Takuro, Nakashima, Kazuhisa, Tsubata, Yukari, Fujita, Yu, Wakui, Hiroshi, Furuta, Megumi, Konishi, Jun Sakakibara, Ohuchi, Mayu, Ando, Yuichi, Mizugaki, Hidenori, Hamada, Akinobu

“…Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older…”
Get full text

Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer by Akagi, Kazumasa, Yagishita, Shigehiro, Ohuchi, Mayu, Hayashi, Yoshiharu, Takeyasu, Yuki, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Yoshida, Tatsuya, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Mukae, Hiroshi, Ohe, Yuichiro, Hamada, Akinobu

“…•We developed a novel method to analyze ramucirumab concentration using LC-MS/MS.•The high concentration group had a high overall response rate and long…”
Get full text

Abstract 4647: Mass spectrometric analysis of oncometabolite 2-hydroxyglutarate in clinical gliomas with the isocitrate dehydrogenase-1 mutation by Hayashi, Mitsuhiro, Aikawa, Hiroaki, Ohno, Makoto, Ichimura, Koichi, Matsushita, Yuko, Ohuchi, Mayu, Mizui, Mariko, Yoshida, Akihiko, Narita, Yoshitaka, Hamada, Akinobu

“…Introduction: Mutations of the isocitrate dehydrogenase (IDH)-1/2 genes frequently occur in certain malignancies, including gliomas. Mutant IDH-1/2 proteins…”
Get full text

Abstract 2797: Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years by Nakahara, Yoshiro, Watanabe, Kageaki, Hosomi, Yukio, Yamanaka, Yuta, Kurata, Takayasu, Horinouchi, Hidehito, Ohe, Yuichiro, Asao, Tetsuhiko, Saeki, Sho, Tsubata, Yukari, Fujita, Yu, Konishi, Jun Sakakibara, Mizugaki, Hidenori, Ohuchi, Mayu, Yagishita, Shigehiro, Hamada, Akinobu

“…Background: Pembrolizumab (Pemb) is a key drug for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, there are limited data…”
Get full text